Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive agents and SGLT-2 inhibitors, which are intended to delay the progression of kidney damage. RAAS inhibitors are the standard of care for CKD. In 2021, AstraZeneca’s Farxiga (dapagliflozin) became the first SGLT-2 inhibitor to demonstrate a renoprotective effect in a dedicated CKD outcomes trial and to receive formal approval from the FDA for the treatment of CKD irrespective of the presence or absence of diabetes. In 2022, Eli Lilly’s Jardiance (empagliflozin) demonstrated renoprotective benefits among CKD patients in the EMPA-KIDNEY trial; this SGLT-2 inhibitor is expected to receive a label expansion to CKD in 2023. Johnson & Johnson’s Invokana (canagliflozin) also demonstrated renoprotective benefits in diabetic patients with CKD in the CREDENCE trial. Thus, SGLT-2 inhibitors are set to play an increasingly important role in CKD treatment. In 2021, Bayer’s Kerendia (finerenone), a mineralocorticoid receptor antagonist, was approved for CKD after demonstrating renoprotective and cardioprotective benefits in type 2 diabetes patients with CKD in the FIDELIO-DKD and FIGARO-DKD trials. Supported by insights from thought leaders, we analyze the challenges associated with marketing drugs to treat an increasingly dynamic and complex disease.
Questions answered
Does the inclusion of cardiovascular endpoints in clinical trials of select CKD therapies confer a competitive advantage once the therapies become commercially available?
Are SGLT-2 inhibitors set to become the standard-of-care therapy for CKD?
How do KOLs view the advantages and disadvantages of current therapies and the mechanisms of action of emerging therapies?
What are the greatest unmet needs in CKD? Which drugs in development will fulfill these unmet needs?
What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Market share of drug classes for chronic kidney disease: 2022
Market share of drug classes for chronic kidney disease: 2032
Chronic kidney disease SWOT analysis
Market drivers and constraints
What factors are driving the market for chronic kidney disease?
What factors are constraining the market for chronic kidney disease?
Annual sales for total chronic kidney disease by chronic kidney disease stage: 2022-2032
Annual sales of drug classes for total chronic kidney disease: 2022-2032
Annual patient share of key drug classes for stage 2 chronic kidney disease: 2022-2032
Annual patient share of key drug classes for stage 3 chronic kidney disease: 2022-2032
Annual patient share of key drug classes for stage 4 chronic kidney disease: 2022-2032
Annual patient share of key drug classes for stage 5 chronic kidney disease: 2022-2032
Drug-class-specific trends
Annual sales of SGLT-2 inhibitors in chronic kidney disease in major markets: 2022-2032
Annual patient share of SGLT-2 inhibitors in chronic kidney disease in the United States: 2022-2032
Annual sales of SGLT-2 inhibitors in chronic kidney disease in the United States: 2022-2032
Annual patient share of SGLT-2 inhibitors in chronic kidney disease in Europe: 2022-2032
Annual sales of SGLT-2 inhibitors in chronic kidney disease in Europe: 2022-2032
Annual patient share of SGLT-2 inhibitors in chronic kidney disease in Japan: 2022-2032
Annual sales of SGLT-2 inhibitors in chronic kidney disease in Japan: 2022-2032
Annual sales of mineralocorticoid receptor antagonists in chronic kidney disease in the United States: 2022-2032
Annual sales of mineralocorticoid receptor antagonists in chronic kidney disease in Europe: 2022-2032
Annual sales of mineralocorticoid receptor antagonists in chronic kidney disease in Japan: 2022-2032
Annual patient share of mineralocorticoid receptor antagonists in chronic kidney disease in the United States: 2022-2032
Annual patient share of mineralocorticoid receptor antagonists in chronic kidney disease in Europe: 2022-2032
Annual patient share of mineralocorticoid receptor antagonists in chronic kidney disease in Japan: 2022-2032
Semaglutide
Major-Market patient share of semaglutide in chronic kidney disease: 2022 - 2032
Major-Market annual sales of semaglutide in chronic kidney disease: 2022 - 2032
Forecast
Market Forecast Assumptions
Market Forecast Dashboard
Etiology and Pathophysiology
Disease overview
Etiology
Risk factors for chronic kidney disease
Pathophysiology
Classification of chronic kidney disease by estimated glomerular filtration rate
Classification of chronic kidney disease by proteinuria
Key pathways and drug targets
Drug targets
Epidemiology
Key findings
Epidemiology populations
Disease definition
Methods and sources used
Prevalent cases of chronic kidney disease: 2022-2032
Diagnosed prevalent cases of chronic kidney disease: 2022-2032
Drug-treated prevalent cases of chronic kidney disease: 2022-2032
Current Treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for chronic kidney disease
Key current therapies
Overview
Mechanism of action of key current drug classes used for chronic kidney disease
Current treatments used for chronic kidney disease
Market events impacting the use of key current therapies for chronic kidney disease
Dapagliflozin
Advantages and disadvantages of dapagliflozin
Key results from select clinical trials investigating dapagliflozin for the treatment of chronic kidney disease
Expert insight: dapagliflozin
Empagliflozin
Advantages and disadvantages of empagliflozin
Key results from select clinical trials investigating empagliflozin for the treatment of chronic kidney disease
Expert insight: empagliflozin
Canagliflozin
Advantages and disadvantages of canagliflozin
Key results from select clinical trials investigating canagliflozin for the treatment of chronic kidney disease
Expert insight: canagliflozin
Advantages and disadvantages of RAAS inhibitors
Expert insight: RAAS inhibitors
Other antihypertensive drug classes
Expert insight: other antihypertensives
Medical practice
Overview
Factors influencing drug selection in chronic kidney disease
Treatment decision tree for chronic kidney disease: United States
Treatment decision tree for chronic kidney disease: Europe
Treatment decision tree for chronic kidney disease: Japan
Unmet Need Overview
Current and future attainment of unmet needs in chronic kidney disease
Top unmet needs in chronic kidney disease: current and future attainment
Expert insight: unmet need in chronic kidney disease
Drug Pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging Therapies
Key findings
Key emerging therapies
Key therapies in development for chronic kidney disease
Estimated launch dates of key emerging therapies for the treatment of chronic kidney disease
Key results from select clinical trials investigating finerenone for the treatment of chronic kidney disease
Key ongoing clinical trials of finerenone in the treatment of chronic kidney disease
Analysis of the clinical development program for finerenone
Expert insight: finerenone
Expectations for launch and sales opportunity of finerenone in chronic kidney disease
Key results from select clinical trials investigating semaglutide for the treatment of chronic kidney disease
Key ongoing clinical trials of semaglutide in the treatment of chronic kidney disease
Analysis of the clinical development program for semaglutide
Expert insight: semaglutide
Expectations for launch and sales opportunity of semaglutide in chronic kidney disease
Renal autologous cell therapies profile
Key ongoing clinical trials of renal autologous cell therapies in the treatment of chronic kidney disease
Analysis of the clinical development program for renal autologous cell therapies
Expert insight: REACT
Expectations for launch and sales opportunity of renal autologous cell therapy in chronic kidney disease
Early-phase pipeline analysis
Select compounds in early-phase development for chronic kidney disease
Key discontinuations and failures in chronic kidney disease
Access & Reimbursement Overview
Region-specific reimbursement practices
Key market access considerations in chronic kidney disease: United States
General reimbursement environment: United States
Key market access considerations in chronic kidney disease: EU5
General reimbursement environment: EU5
Key market access considerations in chronic kidney disease: Japan
General reimbursement environment: Japan
Appendix
Abbreviations
Chronic kidney disease bibliography
Dwaipayan Chatterjee, M.Pharm.
Dwaipayan Chatterjee, M.Pharm., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders analyst. Mr. Chatterjee authors reports on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.